
India

HOLD (no change)

Consensus ratings*: Buy 19	Hold 8	Sell 5
Current price:		Rs3,248
Target price:		Rs3,450
Previous target:		Rs3,450
Up/downside:		6.2%
InCred Research / Consensus:		-4.6%
Reuters:		
Bloomberg:		TRP IN
Market cap:	US\$	15,140m
	Rs1,0	99,357m
Average daily turnover:	U	S\$19.4m
	Rs	1411.6m
Current shares o/s:		338.4m
Free float: *Source: Bloomberg		28.7%

Key changes in this note

Revise FY25F/26F EPS by -4%/2%.



Relative (76)	(1.0)	2.0 20.0
Major shareholders		% held
Promoters		71.3
BlackRock		1.3
Kotak Mahindra MF		1.2

Research Analyst(s)



Praful BOHRA T (91) 22 4161 1552 E praful.bohra@incredresearch.com Yogesh SONI T (91) 22 4161 1566 E yogesh.soni@incredresearch.com

Torrent Pharmaceuticals Ltd

Weak quarter; long-term story intact

- Muted 3Q performance, with a 3% YoY growth. India growth at 12% was healthy; currency depreciation hit an otherwise healthy growth in Brazil.
- Margin continues to sustain at an elevated level of 32.5%. Margin, in our view, should continue to expand by 50-100bp for the next few years.
- Revise our FY25F/26F estimates by -4%/2%, respectively. Maintain HOLD rating on the stock with an unchanged target price of Rs3,450.

Muted performance; Brazil real depreciation dents growth

Torrent Pharmaceuticals or TPL posted a muted 3QFY25 performance, with a 3% YoY growth, 6% below our/Bloomberg consensus estimates. Growth was impacted due to dismal performance in Brazil and RoW markets. India business growth was 12% YoY led by cardiac, gastrointestinal and diabetes therapies which was partly offset by slow CNS market. Growth was driven by volume (1.5%), price (8%) and new products (2.5%). The consumer segment grew its reach to touch 75,000 outlets (72,000 in 2QFY25). Brazil business declined by 7% YoY due to currency depreciation. In CC terms, Brazil business grew by 10% YoY. TPL expects a high level of price hike (in double digits) in Brazil in FY26F to compensate for the currency-related loss. Germany business grew by 4% YoY in CC terms led by incremental tender wins. The US business was flat at US\$32m. Revenue was impacted by the scheduled shutdown of its insulin plant (Rs750-800m impact). The facility resumed dispatches from Jan 2025 and will continue the abovementioned run-rate, recouping previous supplies as well.

Consistent strong performance on the margin front

TPL's 3QFY25 margin remained stable at an elevated level of 32.5% (as guided earlier), despite a 50bp QoQ decline in gross margin due to lower SG&A expenses. In 9MFY25, TPL expanded its margin by 110bp YoY and has already achieved its guidance of 50-100bp annual improvement. Margin in 4QFY25F is expected to sustain at the current level as TPL, with its sizeable presence in the branded generics market, can consistently take price hikes and sustain its above-industry margin. Further, with the US likely to turn profitable in FY26F and the insulin business back on track, we believe the 50-100bp margin expansion shouldn't be an issue.

All set for GLP-1 opportunity

TPL expects to be in the first wave of launch of GLP-1 drugs in India and Brazil. In Brazil, it expects to be present in Semaglutide when the market opens up in 1QCY26F.

Retain HOLD rating on the stock with an unchanged TP of Rs3,450

Our FY25F/26F EPS estimates stand revised by -4%/2%, respectively. Despite the recent price correction, the risk-reward ratio is still not in favour (43x FY26F EPS). We retain our HOLD rating on the stock with an unchanged target price of Rs3,450. Slowdown in India is a downside risk while better-than-expected margin trajectory is an upside risk.

Financial Summary	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Revenue (Rsm)	85,080	96,200	107,280	115,969	131,515
Operating EBITDA (Rsm)	24,310	28,420	33,680	37,609	44,064
Net Profit (Rsm)	7,770	12,450	16,560	19,312	25,848
Core EPS (Rs)	32.0	36.8	47.1	57.1	76.4
Core EPS Growth	(13.4%)	14.8%	28.0%	21.2%	33.8%
FD Core P/E (x)	101.39	88.31	68.97	56.93	42.53
DPS (Rs)	24.0	22.0	30.0	30.0	30.0
Dividend Yield	0.74%	0.68%	0.92%	0.92%	0.92%
EV/EBITDA (x)	46.64	40.28	33.51	30.03	25.26
P/FCFE (x)	32.25	47.37	17.64	41.82	18.91
Net Gearing	58.5%	73.7%	43.1%	38.8%	14.8%
P/BV (x)	18.47	17.74	16.04	14.15	11.77
ROE	18.4%	20.5%	24.4%	26.4%	30.2%
% Change In Core EPS Estimates				(4.24%)	2.09%
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Pharmaceuticals | India Torrent Pharmaceuticals Ltd | January 25, 2025

(Rsm)	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	Y-o-Y (%)	Q-o-Q (%)
Revenue	24,910	24,910	25,910	26,600	27,320	27,450	28,590	28,890	28,090	3%	-3%
Consumption of raw materials	7,300	7,040	6,500	6,600	6,970	6,790	6,940	6,780	6,730	-3%	-1%
as % of sales	29.3%	28.3%	25.1%	24.8%	25.5%	24.7%	24.3%	23.5%	24.0%		
Employee costs	4,230	4,410	4,990	5,030	4,960	4,860	5,500	5,430	5,490	11%	1%
as % of sales	17.0%	17.7%	19.3%	18.9%	18.2%	17.7%	19.2%	18.8%	19.5%		
R&D costs	1,230	1,500	1,290	1,320	1,300	1,390	1,350	1,450	1,510	16%	4%
as % of sales	4.9%	6.0%	5.0%	5.0%	4.8%	5.1%	4.7%	5.0%	5.4%		
Other expenditure	4910	4690	5220	5400	5400	5580	5760	5840	5220	-3%	-11%
as % of sales	19.7%	18.8%	20.1%	20.3%	19.8%	20.3%					
EBITDA	7,240	7,270	7,910	8,250	8,690	8,830	9,040	9,390	9,140	5%	-3%
Margin (%)	29.1%	29.2%	30.5%	31.0%	31.8%	32.2%	31.6%	32.5%	32.5%		
Depreciation	1,930	1,960	1,910	2,010	2,130	2,030	1,970	1,980	1,990		
Other income	-100	90	340	260	-330	310	240	-160	330		
Interest	1,020	1,070	1,030	910	800	800	750	640	570		
PBT	4,190	4,330	5,310	5,590	5,430	6,310	6,560	6,610	6,910	27%	5%
Total tax	1,360	1,460	1,530	1,730	1,880	1,820	1,990	2,080	1,880		
Tax rate (%)	32.5%	33.7%	28.8%	30.9%	34.6%	28.8%	30.3%	31.5%	27.2%		
PAT before MI	2,830	2,870	3,780	3,860	3,550	4,490	4,570	4,530	5,030	42%	11%
Minority interest (MI)	0	0	0	0	0	0	0	0	0		
Adj. PAT before extraordinary items	2,830	2,870	3,780	3,860	3,550	4,490	4,570	4,530	5,030	42%	11%
Extraordinary expenses	0	0	0	0	880	0	0	0	0		
Reported PAT	2,830	2,870	3,780	3,860	4,430	4,490	4,570	4,530	5,030	14%	11%
No. of shares	338.4	338.4	338.5	338.5	338.5	338.5	338.5	338.5	338.5		
EPS	8.4	8.5	11.2	11.4	10.5	13.3	13.5	13.4	14.9		

Figure 2: Margin profile											
Margins (%)	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	Y-o-Y (bp) (Q-o-Q (bp)
Gross	71%	72%	75%	75%	74%	75%	76%	77%	76%	155	-49
EBITDA	29%	29%	31%	31%	32%	32%	32%	33%	33%	73	4
Adj.PAT	11%	12%	15%	15%	13%	16%	16%	16%	18%	491	223
Effective tax rate	32%	34%	29%	31%	35%	29%	30%	31%	27%	-742	-426
								SOURCE: INCF	RED RESEAR	CH, COMPAN	Y REPORTS

Figure 3: Revenue brea	k-up										
(Rsm)	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	Y-o-Y (%) G	λ−ο-Q (%)
US formulations	2,910	2,800	2,930	2,480	2,740	2,620	2,590	2,680	2,710	-1%	1%
% total revenue	11.7%	11.2%	11.3%	9.3%	10.0%	9.5%	9.1%	9.3%	9.6%		
Europe	2,410	2,530	2,580	2,660	2,700	2,800	2,840	2,880	2,820	4%	-2%
% total revenue	9.7%	10.2%	10.0%	10.0%	9.9%	10.2%	9.9%	10.0%	10.0%		
Latin America	2,480	3,180	1,900	2,520	3,120	3,720	1,960	2,630	2,910	-7%	11%
% total revenue	10.0%	12.8%	7.3%	9.5%	11.4%	13.6%	6.9%	9.1%	10.4%		
India formulations	12,590	12,570	14,260	14,440	14,150	13,800	16,350	16,320	15,810	12%	-3%
% total revenue	50.5%	50.5%	55.0%	54.3%	51.8%	50.3%	57.2%	56.5%	56.3%		
ROW, CRAMS & others	4,520	3,830	4,240	4,500	4,610	4,510	4,850	4,380	3,840	-17%	-12%
% total revenue	18.1%	15.4%	16.4%	16.9%	16.9%	16.4%	17.0%	15.2%	13.7%		
Total revenue	24,910	24,910	25,910	26,600	27,320	27,450	28,590	28,890	28,090	3%	-3%
SOURCES: INCRED RESEARCH, COMPANY REPO					REPORTS						


Figure 4: Actuals versus estimates					
	Actuals	Incred Est.	Variance (%)	Bloomberg Est.	Variance (%)
Revenue (Rs m)	28,090	29,929	(6.1)	30,028	(6.5)
EBITDA (Rs m)	9,140	9,796	(6.7)	9,764	(6.4)
Margin (%)	32.5	32.7		32.5	
PAT (Rs m)	5,030	5,153	(2.4)	5,137	(2.1)
			SOURC	E: INCRED RESEARCH, C	COMPANY REPORTS

Figure 5: : Our revised earnin	gs estimates					
		FY25F			FY26F	
	Old	New	Variance (%)	Old	New	Variance (%)
Revenue (Rsm)	1,19,422	1,15,969	-2.9	1,33,191	1,31,515	-1.3
EBITDA (Rsm)	38,981	37,609	-3.5	44,283	44,064	-0.5
Margin (%)	32.6	32.4		33.2	33.5	
PAT (Rsm)	20,168	19,312	-4.2	25,319	25,848	2.1
				SOURCE: INCRI	ED RESEARCH, CO	MPANY REPORTS

InCred Equities

Pharmaceuticals | India Torrent Pharmaceuticals Ltd | January 25, 2025






InCred Equities

Pharmaceuticals | India Torrent Pharmaceuticals Ltd | January 25, 2025

BY THE NUMBERS



(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Net Revenues	85,080	96,200	107,280	115,969	131,515
Gross Profit	60,650	68,850	80,420	88,127	100,707
Operating EBITDA	24,310	28,420	33,680	37,609	44,064
Depreciation And Amortisation	(6,620)	(7,070)	(8,080)	(7,950)	(8,500)
Operating EBIT	17,690	21,350	25,600	29,659	35,564
Financial Income/(Expense)	(2,550)	(3,330)	(3,540)	(2,670)	(2,100)
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	1,970	450	580	600	1,000
Profit Before Tax (pre-El)	17,110	18,470	22,640	27,589	34,464
Exceptional Items	(4,850)		880		
Pre-tax Profit	12,260	18,470	23,520	27,589	34,464
Taxation	(4,490)	(6,020)	(6,960)	(8,277)	(8,616)
Exceptional Income - post-tax					
Profit After Tax	7,770	12,450	16,560	19,312	25,848
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	7,770	12,450	16,560	19,312	25,848
Recurring Net Profit	10,844	12,450	15,940	19,312	25,848
Fully Diluted Recurring Net Profit	10,844	12,450	15,940	19,312	25,848

Cash Flow					
(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
EBITDA	24,310	28,420	33,680	37,609	44,064
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(3,519)	(182)	4,180	(14,689)	(4,882)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	(2,762)	(4,557)	(5,200)	(8,277)	(8,616)
Net Interest (Paid)/Received	(2,550)	(3,330)	(3,540)	(2,670)	(2,100)
Tax Paid	2,669	(1,674)	(3,120)	(6,207)	(7,516)
Cashflow From Operations	18,030	23,681	32,660	14,643	30,565
Capex	(1,970)	(4,152)	(2,990)	(3,000)	(3,000)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments		(20,000)			
Other Investing Cashflow					
Cash Flow From Investing	16,060	(471)	29,670	11,643	27,565
Debt Raised/(repaid)					
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(6,770)	(8,630)	(10,150)	(10,153)	(10,153)
Preferred Dividends					
Other Financing Cashflow	(9,430)	10,471	(16,990)	(10,362)	(4,164)
Cash Flow From Financing	(16,200)	1,841	(27,140)	(20,516)	(14,317)
Total Cash Generated	(140)	1,370	2,530	(8,872)	13,248
Free Cashflow To Equity	34,090	23,210	62,330	26,287	58,131
Free Cashflow To Firm	36,640	26,540	65,870	28,957	60,231

SOURCE: INCRED RESEARCH, COMPANY REPORTS

BY THE NUMBERS...cont'd

Pharmaceuticals | India

Torrent Pharmaceuticals Ltd | January 25, 2025

(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Cash And Equivalents	5,900	7,270	9.800	928	14,176
Total Debtors	16,330	19,440	18,440	23,194	26,303
Inventories	24.620	22.300	22.790	28,992	32.879
Total Other Current Assets	4,800	4,280	5,080	5,798	6,576
Total Current Assets	51,650	53,290	56,110	58,912	79,934
Fixed Assets	32,470	34,600	35,780	30,830	25,330
Total Investments	420	430	320	320	320
Intangible Assets	38,050	54,270	49,210	49,210	49,210
Total Other Non-Current Assets	8,410	7,530	9,190	9,190	9,190
Total Non-current Assets	79,350	96,830	94,500	89,550	84,050
Short-term Debt	19,100	28,010	23,340	23,340	23,340
Current Portion of Long-Term Debt		20,010	20,010	20,010	20,010
Total Creditors	16,740	16.790	20,890	17,758	19,598
Other Current Liabilities	8,310	9.670	10,030	10,147	11,199
Total Current Liabilities	44,150	54,470	54,260	51,246	54,136
Total Long-term Debt	21,600	24,960	16,040	7,748	4,684
Hybrid Debt - Debt Component	21,000	21,000	10,010	.,	.,
Total Other Non-Current Liabilities	5,720	8,710	11,750	11,750	11,750
Total Non-current Liabilities	27,320	33,670	27,790	19,498	16,434
Total Provisions	,	,	,	,	,
Total Liabilities	71,470	88,140	82,050	70,743	70,570
Shareholders Equity	59.530	61.980	68.560	77.719	93,413
Minority Interests	,	. ,	,	, -	,
Total Equity	59.530	61,980	68.560	77,719	93,413
Key Ratios					
	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Revenue Growth			11.5%	8.1%	13.4%
	6.3%	13.1%			
Operating EBITDA Growth	6.3%	13.1% 16.9%	18.5%	11.7%	17.2%
Operating EBITDA Growth Operating EBITDA Margin					
Operating EBITDA Growth	(2.2%)	16.9%	18.5%	11.7%	17.2% 33.5% (40.92)
Operating EBITDA Growth Operating EBITDA Margin	(2.2%) 28.6%	16.9% 29.5%	18.5% 31.4%	11.7% 32.4%	17.2% 33.5%
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs)	(2.2%) 28.6% (102.82)	16.9% 29.5% (135.03)	18.5% 31.4% (87.40)	11.7% 32.4% (89.11)	17.2% 33.5% (40.92)
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs)	(2.2%) 28.6% (102.82) 175.89	16.9% 29.5% (135.03) 183.13	18.5% 31.4% (87.40) 202.57	11.7% 32.4% (89.11) 229.63	17.2% 33.5% (40.92) 276.01
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover	(2.2%) 28.6% (102.82) 175.89 6.94	16.9% 29.5% (135.03) 183.13 6.41	18.5% 31.4% (87.40) 202.57 7.23	11.7% 32.4% (89.11) 229.63 11.11	17.2% 33.5% (40.92) 276.01 16.94
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate	(2.2%) 28.6% (102.82) 175.89 6.94	16.9% 29.5% (135.03) 183.13 6.41	18.5% 31.4% (87.40) 202.57 7.23	11.7% 32.4% (89.11) 229.63 11.11	17.2% 33.5% (40.92 276.01 16.94 25.0%
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio	(2.2%) 28.6% (102.82) 175.89 6.94 36.6%	16.9% 29.5% (135.03) 183.13 6.41 32.6%	18.5% 31.4% (87.40) 202.57 7.23 29.6%	11.7% 32.4% (89.11) 229.63 11.11 30.0%	17.2% 33.5% (40.92 276.0° 16.94 25.0% 68.6§
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days	(2.2%) 28.6% (102.82) 175.89 6.94 36.6% 67.70	16.9% 29.5% (135.03) 183.13 6.41 32.6% 67.86	18.5% 31.4% (87.40) 202.57 7.23 29.6% 64.44	11.7% 32.4% (89.11) 229.63 11.11 30.0% 65.52	17.2% 33.5% (40.92 276.01 16.94 25.0% 68.69 366.51
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days	(2.2%) 28.6% (102.82) 175.89 6.94 36.6% 67.70 384.20	16.9% 29.5% (135.03) 183.13 6.41 32.6% 67.86 313.09	18.5% 31.4% (87.40) 202.57 7.23 29.6% 64.44 306.36	11.7% 32.4% (89.11) 229.63 11.11 30.0% 65.52 339.43	17.2% 33.5% (40.92 276.01 16.94 25.0% 68.65 366.51 221.25
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days	(2.2%) 28.6% (102.82) 175.89 6.94 36.6% 67.70 384.20 278.12	16.9% 29.5% (135.03) 183.13 6.41 32.6% 67.86 313.09 223.74	18.5% 31.4% (87.40) 202.57 7.23 29.6% 64.44 306.36 256.02	11.7% 32.4% (89.11) 229.63 11.11 30.0% 65.52 339.43 253.34	17.2% 33.5% (40.92) 276.01 16.94

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd. (formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. While every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which is believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made (information barriers and other arrangements may be established, where necessary, to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short-term views, etc.) that are inconsistent with and reach a different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

Research Analyst or his/her relative(s) or InCred Research Services Private Limited or our associate may have any financial interest in the subject company.

Research Analyst or his/her relatives or InCred Research Services Limited or our associates may have actual or beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the Research Report.

Research Analyst or his/her relative or InCred Research Services Private Limited or our associate entities may have any other material conflict of interest at the time of publication of the Research Report.

In the past 12 months, IRSPL or any of its associates may have:

- a) Received any compensation/other benefits from the subject company,
- b) Managed or co-managed public offering of securities for the subject company,
- c) Received compensation for investment banking or merchant banking or brokerage services from the subject company,
- d) Received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company

We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.

Research Analyst may have served as director, officer, or employee in the subject company.

We or our research analyst may engage in market-making activity of the subject company.

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his
 or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and
 autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based on any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in this report and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.

InCred Research Services Private Limited

Research Analyst SEBI Registration Number: INH000011024

Registered Office: Unit No 1203, 12th Floor, B Wing, The Capital, C-70, G Block, BKC, Bandra (E), Mumbai – 400051 Phone: +91-22-6844-6100 Corporate Office: 05th floor, Laxmi Towers, Plot No. C-25, G Block, Bandra – Kurla Complex, Bandra (East), Mumbai – 400051 Phone: +91-22-4161-1500 Name of the Compliance Officer: Mr. Yogesh Kadam Email ID: compliance@incredresearch.com, Phone No: +91-22-41611539 For any queries or grievances, you may contact the Grievance Officer. Name of the Grievance Officer: Mr. Rajarshi Maitra Phone no. +91-022-41611546 Email ID: rajarshi.maitra@incredresearch.com CIN: U74999MH2016PTC287535 Pharmaceuticals | India Torrent Pharmaceuticals Ltd | January 25, 2025

Recommendation	Framework
Stock Ratings	Definition:
Add	The stock's total return is expected to exceed 10% over the next 12 months.
Hold	The stock's total return is expected to be between 0% and positive 10% over the next 12 months.
Reduce	The stock's total return is expected to fall below 0% or more over the next 12 months.
	return of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net ne stock. Stock price targets have an investment horizon of 12 months.
Sector Ratings	Definition:
Overweight	An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.
Neutral	A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.
Underweight	An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.
Country Ratings	Definition:
Overweight	An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.
Neutral	A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.
Underweight	An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark.